Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have significantly improved the treatment of hormone receptor (HR)-positive breast cancer, while immune checkpoint inhibitors have reshaped therapeutic approaches for triple-negative breast cancer. The gene discussed is CDK4; the disease is triple-negative breast carcinoma.